The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,683,381 in first-year total cost, median $217,938.
Most frequent study sections
- Special Emphasis Panel[ZAI1 LR-M (M1)]14
- Special Emphasis Panel[ZAI1 LR-M (M2)]7
Most frequent institutions
- BENAROYA RESEARCH INST AT VIRGINIA MASON1
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- BROAD INSTITUTE, INC.1
- CASE WESTERN RESERVE UNIVERSITY1
- GEORGIA STATE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Discovery and development of RND pump inhibitors from marine microbial sources1R21AI119311-01 | MINCER, TRACY JOHN | WOODS HOLE OCEANOGRAPHIC INSTITUTION, MA | $340,998 | ZAI1 |
| 2015 | Countering beta-lactam resistance in Pseudomonas aeruginosa1R21AI119043-01 | JIN, SHOUGUANGSCAMPAVIA, LOUIS DANIEL | UNIVERSITY OF FLORIDA, FL | $264,747 | ZAI1 |
| 2015 | Pan-Influenza virus inhibitors: Small molecules that disrupt host ADAR1-viral NS1 interactions1R21AI119297-01 | MANICASSAMY, BALAJI | UNIVERSITY OF CHICAGO, IL | $264,650 | ZAI1 |
| 2015 | Chemical intervention of influenza virus RNA nuclear export1R21AI119304-01 | FONTOURA, BEATRIZ MAGARCIA-SASTRE, ADOLFO | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $263,500 | ZAI1 |
| 2015 | Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrhea1R21AI119327-01 | GULATI, SUNITARAM, SANJAY | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $257,606 | ZAI1 |
| 2015 | Exploiting bacterial uptake as a universal platform for antibacterial development1R21AI119296-01 | HUNG, DEBORAH T | BROAD INSTITUTE, INC., MA | $241,235 | ZAI1 |
| 2015 | Identification and Hit-to-Lead Development of Influenza A Virus Inhibitors1R21AI119196-01 | PLEMPER, RICHARD K. | GEORGIA STATE UNIVERSITY, GA | $236,906 | ZAI1 |
| 2015 | Novel cyclic lipopeptides for treating gram negative bacterial infections1R21AI119288-01 | HOUGHTEN, RICHARD ALLEN | TORREY PINES INST FOR MOLECULAR STUDIES, FL | $222,958 | ZAI1 |
| 2015 | Enhancing Neutrophil Responses to Counter MDR Gram Negative Bacterial Pneumonia1R21AI119042-01 | LEE, JANET SOJUNG | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $221,060 | ZAI1 |
| 2015 | Enzyme therapeutics for biofilm prevention and disruption1R21AI119116-01 | HOWELL, PATRICIA LYNNE | HOSPITAL FOR SICK CHLDRN (TORONTO), ON | $218,520 | ZAI1 |
| 2015 | A Novel Folate Antagonistic Strategy to Treat Drug Resistant Pseudomonas aeruginosa and Enterobacteriaceae1R21AI119287-01 | NGUYEN, LIEM DUY | CASE WESTERN RESERVE UNIVERSITY, OH | $217,938 | ZAI1 |
| 2015 | Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis1R21AI119341-01 | LACY-HULBERT, ADAM | BENAROYA RESEARCH INST AT VIRGINIA MASON, WA | $217,500 | ZAI1 |
| 2015 | Novel Inhibitors of DNA Ligase LigA by Substrate-Assisted Tethered Inhibition1R21AI119316-01 | TONGE, PETER J | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $212,062 | ZAI1 |
| 2015 | Novel antimicrobials targeting type IV pilus and type 2 secretion systems1R21AI119269-01 | DONNENBERG, MICHAEL S | UNIVERSITY OF MARYLAND BALTIMORE, MD | $209,911 | ZAI1 |
| 2015 | Drug Discovery Targeting the Influenza A Virus M2-S31N Proton Channel1R21AI119187-01 | PEREZ, DANIEL RWANG, JUN | UNIVERSITY OF ARIZONA, AZ | $207,587 | ZAI1 |
| 2015 | Drug development targeting influenza A cap-snatching endonuclease1R21AI119321-01 | ARNOLD, EDWARD | RUTGERS, THE STATE UNIV OF N.J., NJ | $206,931 | ZAI1 |
| 2015 | Maltose Targeted Antibiotics1R21AI119115-01 | MURTHY, NIRENRILEY, LEE W | UNIVERSITY OF CALIFORNIA BERKELEY, CA | $204,553 | ZAI1 |
| 2015 | Molecular evolution of Peptide antibiotics for drug-resistant Gram negative bacteria1R21AI119104-01 | WIMLEY, WILLIAM C | TULANE UNIVERSITY OF LOUISIANA, LA | $190,845 | ZAI1 |
| 2015 | Mucosally-delivered HA stem binding antiviral for influenza1R21AI119258-01 | FULLER, DEBORAH H. | UNIVERSITY OF WASHINGTON, WA | $189,124 | ZAI1 |
| 2015 | Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections1R21AI119339-01 | IBRAHIM, ASHRAF S. | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $164,250 | ZAI1 |
| 2015 | Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae1R21AI119114-01 | KIRBY, JAMES E | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $130,500 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.